Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10751 - 10775 of 12169 in total
Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Investigational
Investigational
Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).
Investigational
Experimental
Matched Name: … D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide …
Matched Iupac: … {amino[4-({[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}methyl)phenyl]methylidene …
Experimental
Matched Name: … 3-CHLORO-2,2-DIMETHYL-N-[4-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE …
Matched Iupac: … 3-chloro-2,2-dimethyl-N-[4-(trifluoromethyl)phenyl]propanamide …
Experimental
Matched Name: … N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE …
Matched Iupac: … ({3-[(4-chlorophenyl)carbamoyl]naphthalen-2-yl}oxy)phosphonic acid …
N-Hydroxy-nor-L-arginine (nor-NOHA) is under investigation in clinical trial NCT02009527 (Arginase Inhibition in Ischemia-reperfusion Injury).
Investigational
Matched Synonyms: … (2S)-2-amino-4-(((hydroxyamino)iminomethyl)amino)butanoic acid …
Matched Iupac: … (2S)-2-amino-4-(N'-hydroxycarbamimidamido)butanoic acid …
Panobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).
Investigational
Experimental
Matched Name: … Allyl-{6-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-Hexyl-}-Methyl-Amin …
Matched Iupac: … (6-{[3-(4-bromophenyl)-1-benzofuran-6-yl]oxy}hexyl)(methyl)(prop-2-en-1-yl)amine …
Experimental
Matched Name: … N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide …
Matched Iupac: … (2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[2-(cycloheptylamino)acetyl]pyrrolidine-2-carboxamide …
Experimental
Matched Name: … 3-ETHYL-6-{[(4-FLUOROPHENYL)SULFONYL]AMINO}-2-METHYLBENZOIC ACID …
Matched Iupac: … 3-ethyl-6-(4-fluorobenzenesulfonamido)-2-methylbenzoic acid …
Experimental
Matched Name: … N-({6-[(4-CYANOBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID …
Matched Iupac: … (2R)-2-{6-[(4-cyanophenyl)methoxy]naphthalene-2-sulfonamido}pentanedioic acid …
Experimental
Matched Iupac: … -{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic ... (6R,7S)-7-[(2R,3S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-3-hydroxybutanamido]-7-methoxy-3 …
Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
Investigational
DR-01 is a monoclonal antibody directed against human CD94.
Investigational
XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.
Investigational
CN-201 is a humanized anti-CD3/CD19 bispecific antibody.
Investigational
Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. This drug from BMS was not approved by the FDA due...
Investigational
Matched Iupac: … (4S,7S,10aS)-5-oxo-4-[(2S)-3-phenyl-2-sulfanylpropanamido]-octahydro-2H-pyrido[2,1-b][1,3]thiazepine- …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Withdrawn
Matched Salts cas: … 33032-12-1
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Investigational
Matched Iupac: … oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1( …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Niludipine is a calcium channel blocker.
Experimental
Matched Iupac: … 3,5-bis(2-propoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with...
Vet approved
Matched Iupac: … 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Landiolol is a rapid-acting beta-blocker used for rapid ventricular rate control.
Investigational
Matched Iupac: … [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-{4-[(2S)-2-hydroxy-3-({2-[(morpholine-4-carbonyl)amino] …
Matched Salts cas: … 144481-98-1
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Lomerizine is a diphenylmethylpiperazine calcium channel blocker[A245378, A245383] with relatively selective central nervous system (CNS) effects. This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an example being normal-tension glaucoma.
Experimental
Matched Iupac: … 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Displaying drugs 10751 - 10775 of 12169 in total